Bhavnagri Veer 4
4 · Allogene Therapeutics, Inc. · Filed Sep 17, 2021
Insider Transaction Report
Form 4
Bhavnagri Veer
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2021-09-15$2.27/sh+5,000$11,350→ 426,669 total - Sale
Common Stock
2021-09-15$24.77/sh−5,000$123,845→ 421,669 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-15−5,000→ 112,300 totalExercise: $2.27Exp: 2028-06-25→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]Includes 316 shares of the Issuer's common stock acquired by the reporting person on September 15, 2021 pursuant to an employee stock purchase program.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.64 to $24.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.